Сравнительное клиническое рандомизированное исследование эф фективности и безопасности цернилтона® у пациентов с хрониче ким неинфекционным простатитом


Цитировать

Полный текст

Аннотация

The trial of efficacy and safety of two doses of the drug cernilton® in patients with chronic abacterial prostatitis made in the Research Institute of Urology and I.M. Sechenov Medical Academy in 2008 gave evidence for subjective (NIH-CPSI, Sex-4, IPSS and other scales, QOL) and objective (leucocyte count in prostatic secretion) pronounced anti-inflammatory effects of the drug which persist for at least 6 months. Comparison of the two doses of cernilton® showed significant differences in subjective response of the patients (NIH-CPSI and Symptom Frequency Scale). Cernilton® is recommended as a medication of choice for treatment of patients with chronic abacterial prostatitis.

Об авторах

О И Аполихин

ФГУ НИИ урологии Росмедтехнологий

дир. - проф; ФГУ НИИ урологии Росмедтехнологий

Ю Г Аляев

ММА им. И. М. Сеченова

кафедра урологиизав. - член-кор; ММА им. И. М. Сеченова

А В Сивков

ФГУ НИИ урологии Росмедтехнологий

ФГУ НИИ урологии Росмедтехнологий

А З Винаров

ММА им. И. М. Сеченова

кафедра урологии; ММА им. И. М. Сеченова

В Н Ощепков

ФГУ НИИ урологии Росмедтехнологий

ФГУ НИИ урологии Росмедтехнологий

Н Г Кешишев

ФГУ НИИ урологии Росмедтехнологий

ФГУ НИИ урологии Росмедтехнологий

Д А Бедретдинова

ФГУ НИИ урологии Росмедтехнологий

ФГУ НИИ урологии Росмедтехнологий

Н Д Ахвледиани

ММА им. И. М. Сеченова

кафедра урологии; ММА им. И. М. Сеченова

O I Apolikhin

Yu G Alyaev

A V Sivkov

A Z Vinarov

V N Oschepkov

N G Keshishev

D A Bedretdinova

N D Akhvlediani

Список литературы

  1. Krieger J. N., Ross S. O., Riley D. E. Chronic prostatitis: epidemiology and role of infection. Urology 2002; 60 (6, Suppl.): 8- 12; discus.: 13.
  2. McNaughton Collins M., Barry M. J. Epidemiology of chronic prostatitis. Curr. Opin. Urol. 1998; 8 (1): 33-37.
  3. Pontari M. A. Chronic prostatitis/chronic pelvic pain syndrome. Urol. Clin. N. Am. 2008; 35 (1): 81-89.
  4. Krieger J. N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol. Nefrol. 2004; 56 (2): 99-107.
  5. Лопаткин Н. А. Руководство по урологии. М.; 1998.
  6. Jonsson K., Hedelin H. Chronic abacterial prostatitis: Living with a troublesome disease affecting many aspects of life. Scand. J. Urol. Nephrol. 2008; 1-6.
  7. Chiang P. H., Chiang C. P. Therapeutic effect of transurethral needle ablation in non-bacterial prostatitis: chronic pelvic pain syndrome type IIIa. Int. J. Urol. 2004; 11 (2): 97-102.
  8. Lu M. et al. Alpha-blockers and bioflavonoids in men with chronic non-bacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25 (2): 169-172.
  9. Nickel J. C. et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatititis). Br. J. Urol. Int. 2004; 93 (7): 991-995.
  10. Nickel J. C. et al. Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective maulticenter clinical trial. Urology 2000; 56 (3): 413-417.
  11. Schaeffer A. J. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). J. Urol. (Baltimore) 2005; 173 (3): 845.
  12. Wang W. et al. Effects of antibiotic and anti-inflammatory treatment on serum PSA and free PSA levels in patients with chronic prostatitis IIIA. Zhonghua Nan Ke Xue 2006; 12 (9): 787-790.
  13. Zeng X. et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue 2004; 10 (4): 278-281.
  14. Asakawa K. et al. Effects of cernitin pollen-extract (Cernilton) on inflammatory cytokines in sex-hormone-induced nonbacterial prostatitis rats. Hinyokika Kiyo 2001; 47 (7): 459-465.
  15. Leander G. Preliminary research on the therapeutic effect of Cernilton on chronic prostatovesiculitis. Sven. Lakartid. 1962; 59: 3296-3304.
  16. Aoki A. et al. Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study. Hinyokika Kiyo 2002; 48 (5): 259-267.
  17. Aslamazov E. G. et al. Cernilton in the treatment of prostatic adenoma and chronic prostatitis. Urologia 2007; 1: 52, 54-56.
  18. Dedhia R. C., McVary K. T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. (Baltimore) 2008; 179 (6): 2119-2125.
  19. Kato T. et al. Clinical experience on treatment of chronic prostatitis with cernilton tablet. Hinyokika Kiyo 1970; 16 (4): 192- 195,
  20. Shaplygin L. V., Sivakov A. A. Use of cernilton in the therapy of prostatic adenoma and chronic prostatitits. Urologia 2007; 3: 35-37, 39.
  21. Talpur N. et al. Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats. Mol. Cell. Biochem. 2003; 250 (1-2): 21-26.
  22. Wilt T. et al. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 2000; 2: CD001042.
  23. Xu J., Qian W. Q., Song J. D. A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia. Zhonghua Nan Ke Xue 2008; 14 (6): 533-537.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2010